0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anthelmintic Drugs Market by Drug Class, Animal Type, Route Of Administration, Formulation, Sales Channel - Global Forecast to 2030- Product Image
Anthelmintic Drugs Market by Drug Class, Animal Type, Route Of Administration, Formulation, Sales Channel - Global Forecast to 2030- Product Image
Sale

Anthelmintic Drugs Market by Drug Class, Animal Type, Route Of Administration, Formulation, Sales Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5206457
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anthelmintic Drugs Market grew from USD 3.57 billion in 2024 to USD 3.86 billion in 2025. It is expected to continue growing at a CAGR of 8.05%, reaching USD 5.68 billion by 2030.

Understanding the Global Anthelmintic Market Landscape

In a rapidly evolving global health and veterinary landscape, anthelmintic drugs have emerged as a cornerstone for controlling parasitic infections across human and animal populations. From companion pets to livestock and pediatric populations, these therapeutic agents mitigate the burden of helminthiasis, preserve food security, and safeguard economic stability in agriculture and healthcare sectors. Technological advancements in drug discovery, coupled with increasing awareness of zoonotic risks, have elevated the importance of both novel compounds and established treatments. Meanwhile, shifting demographics, intensified livestock production, and the rising pet ownership trend underscore a sustained demand trajectory.

This executive summary distills critical insights into market dynamics, growth drivers, and emerging challenges that define the anthelmintic space. It offers a strategic lens through which stakeholders can assess transformative shifts, tariff impacts, segmentation nuances, regional differentiations, and competitive landscapes. By synthesizing robust primary interviews, secondary data sources, and expert validations, this analysis equips decision-makers with the clarity needed to prioritize investments, refine go-to-market strategies, and anticipate future inflection points. As regulatory bodies tighten guidelines and innovation accelerates, the landscape for anthelmintic drugs is poised for both disruption and opportunity.

Emerging Forces Reshaping Anthelmintic Innovation and Distribution

The anthelmintic sector is experiencing transformative shifts driven by converging scientific breakthroughs and evolving distribution channels. Precision grooming of drug compounds through advanced screening technologies has accelerated the transition from broad-spectrum agents to targeted therapies that minimize resistance and maximize efficacy. At the same time, digital platforms and e-commerce channels are redefining how veterinarians and consumers procure treatments, enabling faster replenishment cycles and data-driven demand forecasting.

Regulatory shifts are further reshaping innovation incentives, with accelerated approval pathways and harmonized standards emerging to expedite access to critical therapies. Collaborative research ventures between academic institutions, biotech startups, and established pharmaceutical houses have unlocked novel mechanisms of action and novel formulations designed for sustained release in both oral and injectable formats. Moreover, heightened awareness of animal welfare and public health concerns has spurred investment in integrated parasite control programs that combine diagnostics, vaccines, and treatment regimens. These convergent forces are reconfiguring traditional value chains, compelling stakeholders to adopt agile models that balance cost efficiency with scientific rigor.

Analyzing the 2025 U.S. Tariffs and Their Rippling Market Effects

The introduction of new U.S. tariffs in 2025 has created ripples across global supply chains for active pharmaceutical ingredients and finished anthelmintic products. Manufacturers reliant on imported raw materials faced immediate cost upticks, compelling them to reevaluate long-term agreements and secure alternative sourcing routes. These procurement adjustments have, in some cases, translated into selective price increases and renegotiated contract terms with veterinary and human health providers.

Beyond direct input costs, the tariff landscape has influenced cross-border trade flows, prompting strategic realignments among contract manufacturing organizations and distributors. Some players have accelerated plans to localize production within North America to mitigate future tariff exposure, while others have deepened partnerships in tariff-exempt regions to preserve competitive pricing. Simultaneously, the uncertainty surrounding potential tariff extensions and retaliatory measures has underscored the need for robust scenario planning. Stakeholders now prioritize supply chain transparency and dual-sourcing strategies to enhance resilience, ensuring uninterrupted access to critical therapies even amid evolving trade policies.

Deep Dive into Market Segmentation Dynamics

A nuanced understanding of market segmentation is essential for tailoring product development and go-to-market approaches in the anthelmintic domain. The landscape organized by drug class includes benzimidazoles, imidazothiazoles and tetrahydropyrimidines, and macrocyclic lactones, each exhibiting distinct efficacy profiles and resistance patterns. Within animal type, companion animals are further delineated into cats and dogs, food producing animals encompass cattle, poultry, sheep and goat, and swine, while the human segment splits into adult and pediatric populations, each demanding customized dosage forms and safety considerations.

Route of administration plays a pivotal role in adoption, with oral, parenteral, and topical modalities delivering flexibility for diverse use cases and patient compliance requirements. Formulation variations such as injectable, oral suspension, and tablet formats drive convenience and storage stability across field and clinical settings. Meanwhile, sales channels span online pharmacies, retail pharmacies, veterinary distributors, and veterinary hospitals and clinics, reflecting the mosaic of procurement behaviors from direct-to-consumer to institutional bulk purchasing. By integrating these segmentation dimensions, stakeholders can identify high-potential niches, optimize marketing messages, and align distribution footprints to match end-user preferences and regulatory frameworks.

Regional Nuances Driving Anthelmintic Adoption Worldwide

Regional dynamics underpin divergent growth trajectories and adoption rates in the anthelmintic market. In the Americas, mature markets leverage advanced veterinary infrastructure, integrated parasite control programs, and robust reimbursement mechanisms to sustain demand, particularly in livestock applications. Meanwhile, Europe, Middle East & Africa presents a heterogeneous landscape where stringent European Veterinary Medicines Regulations drive innovation in key markets, while emerging economies in the Middle East and Africa prioritize affordable formulations and broad-spectrum agents to address endemic parasitic diseases.

Across Asia-Pacific, rapid urbanization, expanding middle-class pet ownership, and government-led livestock modernization initiatives are fueling the fastest growth rates. Regulatory harmonization efforts within regional blocs are enhancing market entry prospects for new compounds, while expanding cold chain capabilities facilitate the distribution of temperature-sensitive injectable products. Collectively, these regional nuances illustrate the importance of adaptive strategies that balance high-value markets with emerging economies, ensuring tailored offerings, local partnerships, and compliance frameworks that resonate with diverse regulatory and economic environments.

Profiles of Leading Players and Competitive Strategies

Leading organizations in the anthelmintic landscape have established competitive moats through diversified portfolios, strategic alliances, and relentless R&D investments. Publicly listed giants maintain dominance across multiple segments, leveraging integrated pipelines that span patented compounds, generic alternatives, and combination therapies. Collaboration with biotechnology firms and academic research centers has generated a robust pipeline of next-generation molecules designed to overcome resistance and extend treatment duration.

Mid-sized innovators differentiate through niche expertise, focusing on specialty formulations and targeted delivery systems that address unmet clinical needs in both veterinary and human health. These players often engage in licensing deals with regional distributors to accelerate market penetration, adopting agile commercialization models that minimize capital expenditure. Contract manufacturing organizations have similarly consolidated their positions by expanding capacity in tariff-advantaged jurisdictions and investing in quality management systems accredited by leading regulatory bodies. Across the competitive field, a common theme emerges: synergy between scientific excellence and operational resilience defines the leading enterprises poised for sustainable growth.

Strategic Actions to Propel Sustainable Growth

Industry leaders should embrace a multifaceted approach to sustain momentum and capitalize on evolving market dynamics. First, forging strategic partnerships across the value chain-from raw material suppliers to digital health platforms-can unlock synergies, enhance resource utilization, and accelerate time to market. Second, investing in precision dosing technologies and sustained-release formulations will address the twin challenges of efficacy and compliance while differentiating product portfolios.

Third, a proactive stance toward regulatory engagement can expedite approvals and foster trust with oversight agencies, particularly in emerging markets where guidelines are rapidly evolving. Fourth, supply chain resilience must be fortified through dual sourcing, localized production nodes, and advanced analytics for demand forecasting. Fifth, tailored pricing and reimbursement strategies that reflect regional economic realities and payment models will solidify market access. Finally, cultivating talent with cross-functional expertise in parasitology, regulatory affairs, and digital marketing will be essential to translate scientific innovation into commercial success and drive long-term value creation.

Rigorous Approach to Market Research and Analysis

This analysis is founded on a rigorous, multi-stage approach combining primary and secondary research methodologies. In the primary phase, in-depth interviews with industry executives, regulatory experts, and key opinion leaders provided nuanced perspectives on market dynamics, competitive positioning, and technological advancements. Simultaneously, observational visits to manufacturing sites and distribution centers complemented insights into operational capabilities and supply chain vulnerabilities.

The secondary research stage entailed a comprehensive review of peer-reviewed journals, regulatory databases, company filings, and proprietary industry reports to validate market trends, patent landscapes, and policy shifts. Quantitative data points were triangulated across multiple sources to ensure consistency and reliability. Expert panels conducted iterative validation sessions to refine findings, challenge assumptions, and enhance analytical frameworks. The resulting synthesis delivers a high-integrity, actionable roadmap for stakeholders navigating the complex anthelmintic drugs market.

Synthesis of Insights and Future Outlook

The anthelmintic drugs market is characterized by dynamic intersections of science, policy, and commerce. As emerging therapies challenge established paradigms and trade policies redefine cost structures, stakeholders must remain agile while upholding the highest standards of efficacy and safety. Segmentation insights reveal clear avenues for targeted innovation, and regional analyses highlight the imperative of localized strategies. Competitive profiling underscores the value of alliance-driven growth and pipeline diversification.

Collectively, these insights paint a portrait of a market at an inflection point, where strategic foresight and disciplined execution will determine the next generation of leaders. Organizations that harness the full spectrum of analytical rigor-blending empirical data with expert intuition-will be best positioned to deliver impactful treatments, optimize global supply chains, and unlock sustainable value. The future of anthelmintic therapy is bright, but it will require concerted effort, collaboration, and an unwavering commitment to innovation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Benzimidazoles
    • Imidazothiazoles And Tetrahydropyrimidines
    • Macrocyclic Lactones
  • Animal Type
    • Companion Animals
      • Cats
      • Dogs
    • Food Producing Animals
      • Cattle
      • Poultry
      • Sheep And Goat
      • Swine
    • Human
      • Adults
      • Pediatric
  • Route Of Administration
    • Oral
    • Parenteral
    • Topical
  • Formulation
    • Injectable
    • Oral Suspension
    • Tablet
  • Sales Channel
    • Online Pharmacies
    • Retail Pharmacies
    • Veterinary Distributors
    • Veterinary Hospitals And Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco Animal Health Inc.
  • Boehringer Ingelheim GmbH
  • Ceva Santé Animale S.A.
  • Virbac S.A.
  • Vetoquinol S.A.
  • Phibro Animal Health Corporation
  • Dechra Pharmaceuticals PLC
  • Norbrook Laboratories Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anthelmintic Drugs Market, by Drug Class
8.1. Introduction
8.2. Benzimidazoles
8.3. Imidazothiazoles And Tetrahydropyrimidines
8.4. Macrocyclic Lactones
9. Anthelmintic Drugs Market, by Animal Type
9.1. Introduction
9.2. Companion Animals
9.2.1. Cats
9.2.2. Dogs
9.3. Food Producing Animals
9.3.1. Cattle
9.3.2. Poultry
9.3.3. Sheep And Goat
9.3.4. Swine
9.4. Human
9.4.1. Adults
9.4.2. Pediatric
10. Anthelmintic Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.4. Topical
11. Anthelmintic Drugs Market, by Formulation
11.1. Introduction
11.2. Injectable
11.3. Oral Suspension
11.4. Tablet
12. Anthelmintic Drugs Market, by Sales Channel
12.1. Introduction
12.2. Online Pharmacies
12.3. Retail Pharmacies
12.4. Veterinary Distributors
12.5. Veterinary Hospitals And Clinics
13. Americas Anthelmintic Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anthelmintic Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anthelmintic Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Zoetis Inc.
16.3.2. Merck & Co., Inc.
16.3.3. Elanco Animal Health Inc.
16.3.4. Boehringer Ingelheim GmbH
16.3.5. Ceva Santé Animale S.A.
16.3.6. Virbac S.A.
16.3.7. Vetoquinol S.A.
16.3.8. Phibro Animal Health Corporation
16.3.9. Dechra Pharmaceuticals PLC
16.3.10. Norbrook Laboratories Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTHELMINTIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTHELMINTIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTHELMINTIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTHELMINTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTHELMINTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTHELMINTIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 59. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 60. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 61. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 63. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 69. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 107. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 109. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 110. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 112. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 117. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 118. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 120. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 132. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 133. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 134. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 136. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 139. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 141. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 142. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 144. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 171. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 174. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 176. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 188. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 189. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 190. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 192. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 195. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 197. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 198. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 200. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 219. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 221. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 222. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 224. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 230. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 232. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 243. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 245. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 246. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 248. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 251. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 252. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 253. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 254. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 256. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 274. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 276. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 277. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 278. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 279. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 281. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 284. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 285. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 286. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 287. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 289. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 292. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 295. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 297. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 323. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 324. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 325. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 326. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 327. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 329. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 344. MALAYS

Companies Mentioned

The companies profiled in this Anthelmintic Drugs market report include:
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco Animal Health Inc.
  • Boehringer Ingelheim GmbH
  • Ceva Santé Animale S.A.
  • Virbac S.A.
  • Vetoquinol S.A.
  • Phibro Animal Health Corporation
  • Dechra Pharmaceuticals PLC
  • Norbrook Laboratories Limited

Methodology

Methodology DOWNLOAD NOW

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.86 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.68 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anthelmintic Drugs Market Report 2025 - Product Image

Anthelmintic Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Neglected Tropical Disease Treatment Market by Disease Indication, Drug Type, Distribution Channel, End User, Route of Administration, Treatment Approach - Global Forecast to 2030 - Product Image

Neglected Tropical Disease Treatment Market by Disease Indication, Drug Type, Distribution Channel, End User, Route of Administration, Treatment Approach - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Parasitic Diseases Therapeutics - Global Strategic Business Report - Product Image

Parasitic Diseases Therapeutics - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
EUR$5,850USDGBP
Liver Fluke Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Liver Fluke Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
EUR$4,365USDGBP
EUR$4,850USDGBP
Antiparasitic Drugs Market Report 2025 - Product Image

Antiparasitic Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
EUR$4,490USDGBP

About the Anthelmintic Market

Anthelmintic drugs are used to treat parasitic worm infections, such as roundworm, hookworm, and whipworm. These drugs are used to treat a variety of conditions, including gastrointestinal, respiratory, and skin infections. Anthelmintic drugs work by killing the worms or preventing them from reproducing. They can also be used to prevent reinfection. Anthelmintic drugs are part of the larger market of infectious disease drugs, which includes antibiotics, antivirals, and antifungals. These drugs are used to treat a wide range of infectious diseases, from common colds to more serious conditions such as HIV/AIDS. The anthelmintic market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Bayer, and Novartis. These companies offer a range of products, from generic drugs to more specialized treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more